EMA Recommends Granting a Marketing Authorisation for Nirogacestat By Ogkologos - July 3, 2025 157 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adult patients with progressing desmoid tumours Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Immunotherapy treatment fast tracked to treat lung cancer patients in England January 28, 2022 EMA Recommends Extension of Indications for Venetoclax May 14, 2021 ESMO Asia Virtual Congress 2020, 20-22 November October 26, 2020 Determining Fluid Requirements March 26, 2021 Load more HOT NEWS “My First Thought Was My Children:” Young Mom Diagnosed With Triple-Negative... FDA Proposes Rule Prohibiting Menthol Cigarettes Advancing Patient Care Through Focused Innovation Artificial Intelligence Brings Pancreatic Cancer Screening One Step Closer to Reality...
